| Nov 15 |
Loss-Making ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Expected To Breakeven In The Medium-Term
|
| Nov 14 |
ARS Pharmaceuticals Inc (SPRY) Q3 2024 Earnings Call Highlights: Strong Cash Position and NEPHI ...
|
| Nov 13 |
ARS Pharmaceuticals, Inc. (SPRY) Q3 2024 Earnings Call Transcript
|
| Nov 13 |
ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Misses Revenue Estimates
|
| Nov 13 |
ARS Pharmaceuticals GAAP EPS of -$0.20 misses by $0.05, revenue of $2.07M
|
| Nov 13 |
ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
|
| Nov 13 |
Earnings Scheduled For November 13, 2024
|
| Nov 12 |
ARS Pharmaceuticals announces agreement with ALK to commercialize neffy
|
| Nov 11 |
ALK snags EU and Canada rights to anaphylaxis nasal spray Neffy for $145m
|
| Nov 11 |
ARS Pharma Jumps After Inking $145 Million Deal For Epinephrine Nasal Spray
|
